Charlotte's Web Reports Q3 2025 Results

Executive Summary

• Charlotte’s Web reported Q3 2025 revenue of $11.5 M, a year‑over‑year decline of 8.6%, with an unchanged net loss of $5.8 M versus the prior year.
• SG&A expenses fell 23.3% YoY to $9.7 M, driven by manufacturing cost reductions and termination of a promotional rights agreement, positioning the company for approximately $9 M of annualized cost savings in 2026.
• The company completed full internalization of Brightside™ gummy production, launched a Scientific Advisory Board, and advanced its DeFloria IND Phase‑2 clinical trial, signaling strategic diversification beyond consumer CBD products.

Key Details

• Revenue: $11.5 M (down 8.6% YoY)
• Cost of Goods Sold: $7.0 M (up from $5.9 M YoY)
• Gross Profit: $4.5 M (38.9% margin, down from 53.0%) – compression due to a $0.5 M B2B charge‑back reserve and higher COGS during in‑house manufacturing ramp‑up.
• SG&A Expenses: $9.7 M (23.3% lower YoY) – includes $1.8 M amortization reduction from MLB promotional rights termination and personnel cost cuts.
• Operating Loss: $(5.2) M (improved from $(6.0) M YoY)
• Net Loss: $(5.8) M, unchanged YoY; EPS basic & diluted: $(0.04).
• Adjusted EBITDA: $(2.1) M (vs. $(3.9) M YoY).
• Cash & Cash Equivalents: $9.8 M at quarter‑end; total working capital $25.6 M.
• Cost‑Saving Initiatives: Expected $9 M annualized cost reductions in 2026 from manufacturing efficiencies and SG&A cuts.
• Manufacturing Update: Full internalization of Brightside™ hemp‑derived THC gummy production; targeting ~75% of total gummy volume in‑house by 2026.
• Product Launches: Brightside™ Hemp Precision Delta‑9 Gummies, expanded sleep portfolio (5 products), new Knockout THC/CBN gummies, CBG Focus & Attention nootropic gummies, functional mushroom line.
• Scientific Advisory Board: Established to guide medical channel strategy and CME content; chaired by Dr. Marcel Bonn‑Miller.
• Regulatory Outlook: Federal Agriculture‑FDA spending bill introduces potential THC limits; company monitoring legislative developments.
• DeFloria IND Phase 2: FDA clearance for Phase 2 trial of botanical drug for ASD irritability; Charlotte’s Web retains exclusive manufacturing rights.
• Board Appointment: M. Borgia Walker appointed to Board of Directors effective 2025‑11‑01, replacing retiring director Jonathan Atwood.

Notable Quotes

“Q3 2025 marked continued progress in our strategic transformation… we anticipate $9 M of total annualized cost savings in 2026.” – Bill Morachnick, CEO
“Our disciplined cost management and channel optimization continue to reshape Charlotte’s Web's financial profile.” – Erika Lind, CFO

Materiality: Material – Neutral (quarterly earnings release with significant operational, financial, and strategic updates).